The European Molecular Biology Laboratory (EMBL) and Enamine, have collaborated to develop novel small molecules which works against anti-cancer targets. As per the terms of this collaboration, Enamine is providing medicinal chemistry, library synthesis, and biological services to EMBL for their cause and together they expect to focus on creating new cancer therapeutics and novel modes of action. The collaboration comprises the deployment of medicinal chemists who are Full Time Equivalent (FTE), at Enamine.
Millions of Compounds Needed to Up Chemical Diversity at Screening Decks
For many years, the EMBL has been working with Enamine to improve the chemical space of their screening library, stated the Head of Chemical Biology Core Facility at EMBL, Joe Lewis. With the realization that above 2 mn collection of compounds can provide quality compounds, there is a need for increasing the chemical diversity of their screening deck. Thus, Enamine was chosen to outsource for their medicinal chemistry discovery program, as the company can help in the field of drug development and chemical biology.
Integration of Chemistry and Biology Service Portfolio
As per David Will, the Head of Medicinal Chemistry at EMBL, the collaboration with Enamine will help their project’s goal of identifying the targets from phenotypic screens, and then synthesizing and triaging patentable preclinical compounds that are new. The access to the world’s largest collection of building blocks at Enamine will go a long way in developing a preclinical compound. The integration of chemistry and biology service portfolio is apt for this kind of research.
“Our collaboration with EMBL illustrates our established engagement with non-profit academic research institutions and disease foundations in their search for strong and committed partners in the most challenging discovery research projects. We look forward to our continued successful work with EMBL”, concluded Michael Bossert, Head Strategic Alliances at Enamine.
RepliCel Life Sciences Inc., a company which specializes in developing cell therapies for orthopedic and aesthetic conditions, received a U.S. patent on April 25, 2017 for its new, multi-needle dermal injection devices. These devices fit as a solution to soaring need for dermal injection technologies capable of bringing high levels of control and precision to any elements injected into the skin.
The patent received from the U.S. Patent and Trademark Office (USPTO) covers technologies designed to allow both repeatable consistency and unparalleled control of product deposition and needle action. The patent also includes the component developed to numb the skin before using injection, with the intention to reduce, if not eliminate, the requirement for local anesthetic prior to aesthetic injection processes.
RepliCel Inches Closer to Launch of RCI-02 with Patent Issued
The first device being designed under the umbrella of this patent is RCI-02, which will be useful in injecting soft tissue fillers, including hyaluronic acid (“HA”). The device is also being designed for injecting RCS-01 skin rejuvenation and RCH-01 hair restoration products. It is expected to be optimized for other injectable such as biologics, drugs, fat grafts, and biologics.
With this patent, the company’s property portfolio has reached a new milestone. The portfolio already included two European patents for RCI-02. Company officials believe that this multi-needle device will be able to deliver unprecedented reproducibility, reliability, and programmability of 3D skin injections, making desired outcomes a much easier thing to attain for both clinicians and less-experienced injection specialists. The prototypes are estimated to get ready by the third quarter of 2017 for initial usability and functional testing by engineers and end users.
Slow rise in the number of users and an inevitably slow business from ad inventory due to the sluggishly rising user count are expected to bring trouble to Twitter’s revenues. Analysts from Wall Street think that the company’s business is declining and the company is expected to report a year-over-year decline in revenue, which would be the company’s first ever loss, when the earnings are released on Wednesday.
Analysts estimate the company will record profits of around one percent per share on the 2017 Q1 revenue of US$512 mn. If the estimates are correct, the company would have suffered a loss of around 14% as compared to the US$595 mn that the company generated in revenues during the 1st financial quarter of 2016. Twitter has reported year-on-year growth in revenue for every quarter ever since it has gone public in the late 2013.
Declining Number of New Users could also mean Decline in Ad Revenues
Wall Street’s estimates regarding Twitter’s business could be wrong as well, but a decline in business is, of course, bad for the company as it is seeing a plateau when it comes to number of new users. Decline in the number of new users would also directly impact the company’s revenue from ads – the easiest way to generate revenue for a social media company.
But if Wall Street’s analysis proves correct for the company, Twitter has a tough road ahead to frame its slowing revenue stream. If the earnings are indeed low, possibilities of takeover will start doing rounds in business circles. The company was also exploring sale options the previous year but the price tag was a bit high for most companies interested in buying it.
Last year, the company was valued at around US$13 bn, which was when analysts estimated that it could be sold at around US$18 bn. Now that its valuation has come down to US$10.7 bn, it will be interesting to see how much the company is valued for possible suitors.
A recent research conducted by IHS Markit Data found that the Ford Mustang is the best-selling sports car on a global scale. Although the stunning sports car was introduced in the U.S. long back, the company has recently pushed the boundaries of the regional market, making it available worldwide. The result? More than 45,000 Mustang sports cars are sold in 2016, registering 101% growth from 2015.
Six New Countries to Witness Launch of 2018 Mustang
Now available across more than 140 countries of the world, customers outside the U.S. are increasingly inclined to buy the sixth generation version of the car, accounting for nearly a quarter of sales. The 2018 Mustang is expected to be launched in six new countries that include Ivory Coast, Brazil, and the Palau Islands.
Strangely enough, the IHS completely avoided specifying the definition of a sports car when it comes to its rankings. Moreover, it did not reveal data about who the first runner-up sports car in the competition is. The only confirmation received was the accuracy of Ford’s analysis. The IHS has also tracked the popularity of the Porsche 911, BMW 4 Series, the Mazda MX-5, and the Nissan 370z.
China and Germany Exhibit Greatest Demand
Sponsored by the German Federal Ministry of Transport and Digital Infrastructure and other organizations, the Ford Mustang GT is being increasingly being used as a cop car in Germany. Eclipsing the sales of Audi TT and Porsche 911, the American muscle car has been sold at a great pace in spite of the sky-rocketing fuel prices in the country. A cult hit in China, the number of Mustangs sold was more than 88,432 during January 2017. It set the best-ever monthly sales record for that year.
Flaunting the newest 10-speed transmission alongside an upgraded capacity of 5-liter V8, the car is likely to retain its popularity over the oncoming years.